Harold Werner
Co-Founder & Managing Director @ HealthCare Ventures
New York, United States
Harold Werner is a Series B investor at HealthCare Ventures in New York focused on Biotechnology and Medical. Hal Werner is a Managing Director and Co-founder of HealthCare Ventures. Prior to the formation of HealthCare Ventures, Harold served as director of new ventures for Johnson & Johnson Development Corporation. Harold also has served as senior vice president of Robert S. First, Inc., an international health care consulting firm.Harold received his M.B.A. degree from Harvard University
- Total investments:
- 5
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Harold Werner invests in
Stages Harold Werner invests in
Countries Harold Werner invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 2 (40%)
- Medical 1 (20%)
- Health Care 1 (20%)
- Search Engine 1 (20%)
- Pharmaceutical 1 (20%)
Stage
- Series B 2 (40%)
- Series A 1 (20%)
- Series C 1 (20%)
- Debt Financing 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Stemgent works alongside some of the world's leading stem cell scientists in developing innovative technology and application solutions that provide researchers the tools to investigate and understand cellular reprogramming. Our mission is to help simplify and support stem cell research by producing products and services being designed byleading stem cell researchers.SpecialtiesCellular Reprogramming, iPS Cells, Media, Human iPSC Training & Services, mRNA Reprogramming, Stem Cell Research, Custom iPS cell lines, Pluriton, WIT, StainAlive, NutriStem | $10.6M / Series B / Jun 10, 2011 | ||
| Stemgent works alongside some of the world's leading stem cell scientists in developing innovative technology and application solutions that provide researchers the tools to investigate and understand cellular reprogramming. Our mission is to help simplify and support stem cell research by producing products and services being designed byleading stem cell researchers.SpecialtiesCellular Reprogramming, iPS Cells, Media, Human iPSC Training & Services, mRNA Reprogramming, Stem Cell Research, Custom iPS cell lines, Pluriton, WIT, StainAlive, NutriStem | $2.7M / Debt Financing / Nov 25, 2009 | ||
| InfaCare Pharmaceutical, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceuticals for the neonatal and pediatric patient population. Its neonatal product, Stanate, is under development for the pharmacologic treatment of infantile jaundice or hyperbilirubinemia. The company was founded in 2005 and isbased in Trevose, Pennsylvania. | $28M / Series B / Oct 28, 2008 | ||
| Stemgent works alongside some of the world's leading stem cell scientists in developing innovative technology and application solutions that provide researchers the tools to investigate and understand cellular reprogramming. Our mission is to help simplify and support stem cell research by producing products and services being designed byleading stem cell researchers.SpecialtiesCellular Reprogramming, iPS Cells, Media, Human iPSC Training & Services, mRNA Reprogramming, Stem Cell Research, Custom iPS cell lines, Pluriton, WIT, StainAlive, NutriStem | $6.5M / Series A / Jul 18, 2008 | ||
| Avidia, Inc., a biopharmaceutical company, engages in discovering and developing therapeutic proteins. The company offers Avimer therapeutic proteins, which are used to address various therapeutic areas, including autoimmunity, inflammation, oncology, and neurology. Avidia, Inc. was founded in 2003 and is headquartered in Mountain View, California. | $43.8M / Series C / May 09, 2006 |
Co-Investors
About HealthCare Ventures
HealthCare Ventures is a leading life science venture capital firm investing in pre-clinical or early clinical stage, focused companies with potential to transform patient care.
HealthCare Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
James H. Cavanaugh
Managing Director
|
|||
|
John Littlechild
Managing Director & General Partner
|
|||
|
Christopher K. Mirabelli
Managing Director
|
|||
Douglas E. Onsi
Managing Director
|
|||
|
Harold Werner
Co-Founder & Managing Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Harold Werner invest in?
Harold Werner invests primarily in Biotechnology, Medical and Health Care startups, most often at Series B and Series A stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Harold Werner?
Public channels for Harold Werner include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Harold Werner last invest?
The most recent investment recorded for Harold Werner closed in Jun 2011. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
